B-cell lymphoma and melanoma harbor recurrent mutations in the gene encoding the EZH2 histone methyltransferase, but the carcinogenic role of these mutations is unclear. Here we describe a mouse model in which the most common somatic EZH2 gain-of-function mutation (Y646F in human, Y641F in the mouse) can be conditionally expressed. Expression of Ezh2 Y641F in mouse B-cells or melanocytes caused high-penetrance lymphoma or melanoma, respectively. Bcl2 overexpression or p53 loss, but not c-Myc overexpression, further accelerated lymphoma progression, and expression of mutant B-Raf but not mutant N-Ras further accelerated melanoma progression. Although expression of Ezh2 Y641F increased abundance of global H3K27 trimethylation (H3K27me3), it also caused a widespread redistribution of this repressive mark, Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms Author Manuscript including a loss of H3K27me3 associated with increased transcription at many loci. These results suggest that Ezh2 Y641F induces lymphoma and melanoma through a vast reorganization of chromatin structure inducing both repression and activation of polycomb-regulated loci.
INTRODUCTION
Data from several cancer types suggest that dysregulation of polycomb group complexes (PcGs) can contribute to malignant transformation, consistent with the fact that PcG complexes regulate thousands of transcripts responsible for cell fate [1] [2] [3] . The role of PcGmediated gene silencing in cancer is supported by the observation that many cancers harbor higher levels or activating mutations of PcG genes. Moreover, PcG-repressed genes include tumor suppressors like the INK4a/ARF (CDKN2a) locus [4] [5] [6] . EZH2 (Enhancer of Zeste Homolog 2) is the catalytic component of the Polycomb repressive complex group 2 (PRC2) and was first identified in Drosophila for its role in development and differentiation. EZH2 is highly expressed in different types of B-cell tumors 7, 8 , and along with PcG proteins EED and BMI, is critical to B-cell development [9] [10] [11] . Sequencing studies identified frequent mutations in the EZH2 SET-domain (e.g. tyrosine residue 646 (Y646, equivalent to Y641 in the mouse)) in germinal center (GC) diffuse large B-cell lymphoma (DLBCL) and follicular lymphomas [12] [13] [14] . Somatic EZH2 mutations or amplifications also occur in other tumor types, including non-small cell lung cancer, prostate cancer, colon carcinoma and melanoma [15] [16] [17] , whereas loss-of-function events appear in MDS/AML 18 and T-cell ALL 19 . These findings suggest that EZH2 may be a potential therapeutic target beyond lymphoma, with currently five open clinical trials using three different Ezh2 inhibitors (GSK, Epizyme and Constellation).
No mouse model of the most common EZH2 SET-domain mutations is currently available to investigate its cell-dependent in vivo effect or to test the efficacy of EZH2-targeted therapeutics. To understand the role and function of this mutation in malignant progression, we generated a model permitting conditional expression of the mutant protein 'knocked-in' to the native locus with intact cis-regulatory elements. We examined the ability of this allele to promote lymphoid and solid (e.g. melanoma) malignancies by itself, and in co-operation with other oncogenic events, by crossing to mouse strains expressing tissue-specific Crerecombinase.
CD19 CRE/+ Ezh2 Y641F/+ mice expressed Ezh2 transcripts at equal levels ( Supplementary Fig.   1e ). Consistent with a reported gain-of-function of the Y641F mutation in humans 21 , B-cells from 8-week-old CD19 CRE/+ Ezh2 Y641F/+ mice exhibited a ~3-fold increase in H3K27me3 compared to matched B-cells from CD19 CRE/+ Ezh2 +/+ mice and CD19 − cells (Fig. 1b) .
Expression of Ezh2 Y641F had minimal effect on B-cell development in 8-week old mice ( Supplementary Fig. 2a-h ).
To examine the effects of Ezh2 Y641F on B-cell malignancy, we longitudinally observed a cohort of littermate CD19 CRE/+ Ezh2 Y641F/+ and CD19 CRE/+ Ezh2 +/+ animals. In contrast to results employing animals expressing Ezh2 Y641F under the control of a collagen promoter 22 , expression of Ezh2 Y641F from the endogenous locus induced highly penetrant B-cell lymphoma with a median survival of one year (Fig. 1c) . All tumors analyzed (n = 15) from CD19 CRE/+ Ezh2 Y641F/+ mice demonstrated recombination of the Ezh2 allele (not shown) and a CD45+ B220+ CD19+ IgM+ CD43+ CD5+ phenotype; they also expressed the myeloid marker Mac1 (Supplementary Fig. 3a) . Tumor-bearing mice demonstrated disruption of the splenic architecture and expansion of abnormal, large lymphoid cells in the white pulp, with ~50% of animals demonstrating frank leukemia and/or hepatic involvement ( Supplementary Fig. 3b ). Tumors exhibited increased expression of H3K27me3 and were readily transplantable into syngeneic recipients (Fig. 1d , and Supplementary Fig. 3c-e) . Therefore, physiological expression of Ezh2 Y641F in young mice does not markedly perturb the development of B-lymphocytes, but facilitates malignant transformation.
To determine whether genetic alterations detected in human B-cell lymphomas cooperate with Ezh2 Y641F in tumor formation, we transduced hematopoietic progenitors from CD19 CRE/+ Ezh2 +/+ or CD19 CRE/+ Ezh2 Y641F/+ mice with retroviruses encoding Bcl2 or cMyc. Expression of c-Myc subtly increased B-cell lymphocytosis ( Supplementary Fig. 4a ), but did not accelerate tumor formation in CD19 CRE/+ Ezh2 Y641F/+ mice (Fig. 1e) . Consistent with a prior report 22 , recipients of Bcl2-transduced CD19 CRE/+ Ezh2 Y641F/+ hematopoietic progenitors developed advanced B-cell lymphoma much faster than recipients of Bcl2-transduced CD19 CRE/+ Ezh2 +/+ cells ( Fig. 1e , P < 0.001, Supplementary Fig. 4b, c) . Moreover, the combination of somatic p53 inactivation with Ezh2 Y641F expression accelerated lymphoma formation ( Fig. 1f , P < 0.001, Supplementary Fig. 4d,e) . These results suggest that globally increased H3K27me3 cooperates with apoptotic resistance mediated by Bcl2 overexpression or p53 loss to accelerate B-cell transformation, consistent with the co-occurrence of these genetic alterations in human B-cell lymphoma 23 .
In vitro, EZH2 Y641F exhibits decreased H3K27 mono-methylase activity, but increased diand tri-methylase activity compared to EZH2 +/+ 21,24 , suggesting that transformation may require expression of both wild-type and mutant proteins. Consistent with this model, to our knowledge, all human cancers observed to date harboring EZH2 Y641F mutations also retain a wild-type copy of EZH2 13, 15, 17, 23 . To test the requirement of wild-type Ezh2 for tumorigenesis, we determined the tumor latency of CD19 CRE/+ Ezh2 Y641F/Y641F mice. CD19 CRE/+ Ezh2 Y641F/Y641F mice developed splenomegaly and lymphadenopathy with an infiltration of abnormal B220 low Mac1 low B-cells (Fig. 1g, h ) with kinetics and tumor immunophenotype nearly identical to CD19 CRE/+ Ezh2 Y641F/+ mice. Both heterozygous and homozygous mice for the Y641F mutation exhibited elevated levels of H3K27me3 compared to controls (Fig. 1i) . As both alleles from tumors of Ezh2 Y641F/Y641F underwent recombination ( Supplementary Fig. 4f ) and therefore only express mutant Ezh2, these data demonstrate that wild-type Ezh2 function is dispensable for tumorigenesis in cells harboring Ezh2 Y641F mutations. This observation could reflect residual monomethylase activity of the tyrosine to phenylalanine substitution, which may not be a feature of other Y646 mutations of EZH2 21 ; it is also possible that another H3K27 monomethylase (e.g. EZH1) compensates for loss of EZH2 activity in these tumors.
Ezh2 Y641F cooperates with B-Raf but not N-Ras to induce melanoma
In addition to lymphoma, EZH2 Y646 mutations are observed in 3% of human melanoma [25] [26] [27] , with focal amplifications of EZH2 noted in 15 of 262 (5.7%) of cases from the Cancer Genome Atlas (TCGA). As B-RAF V600E or N-RAS Q61R mutations occur in the majority of human melanomas, we tested the ability of the Ezh2 Y641F allele to cooperate with the conditionally activatable mouse alleles of B-Raf V600E (ref. 28 ) or N-Ras Q61R (ref. 29 ) in the presence of the tamoxifen-inducible tyrosinase CRE allele (TyrCRE ERT2 ) 30, 31 . Melanoma was not observed in TyrCRE ERT2 B-Raf V600 as previously described 29, 32 . The inclusion, however, of a heterozygous Ezh2 Y641F mutation rapidly accelerated tumorigenesis of un-pigmented, non-metastatic melanoma in the context of BRaf V600E activation and combined B-Raf V600E Pten L/+ (Fig. 2a-c ). Ezh2 Y641F , therefore, cooperates with mutant B-RAF (± haploinsufficiency of PTEN) in melanoma formation and maintenance.
In contrast, melanocyte-specific activation of Ezh2 Y641F in the presence of N-Ras Q61R did not accelerate melanomagenesis, with or without p16 Ink4a loss (Fig. 2d) . As B-RAF is thought to be a downstream effector of N-RAS signaling to MEK/ERK, the differing abilities of N-Ras Q61R and B-Raf V600E to promote melanoma in the context of Ezh2 Y641F was unexpected. We carefully examined data from prior melanoma sequencing studies [25] [26] [27] using cBIOPORTAL 15, 17 . In accord with our murine genetic results, EZH2 mutations in human melanoma co-occur at a significant frequency with activating mutations in B-RAF (P = 0.006), and are mutually exclusive with N-RAS mutations (P = 0.004) ( Supplementary   Fig. 5 ). These results suggest that while RAF/MEK/ERK activation synergizes with EZH2 Y641F mutations in melanoma formation, a RAF-independent aspect of mutant RAS signaling renders the oncogenic effects of mutant EZH2 irrelevant to transformation.
We performed experiments to address the cooperation of EZH2 mutation with B-RAF but not N-RAS. We observed that the expression of N-RAS and B-RAF is not altered by the presence of the Y641F mutation (data not shown). A major pathway activated by N-RAS but not B-RAF is PI3K-AKT. To determine if mutant N-RAS but not B-RAF inhibits the oncogenic effects of Ezh2 Y641F , we transduced primary human melanocytes with B-RAF V600E , N-RAS Q61K or PIK3CA-CAAX, a membrane-bound and constitutively active catalytic subunit of PI3K. As previously reported 33 , expression of each resulted in oncogene-induced senescent, as characterized by increased expression of p16 INK4a (Fig. 2e) , ceased proliferation and flat enlarged morphology (data not shown). Neither B-RAF V600E , N-RAS Q61K nor PIK3CA-CAAX significantly altered EZH2 mRNA levels ( Fig. 2f) , however, N-RAS Q61K and PIK3CA-CAAX, but not B-RAF V600E , resulted in a global decrease in H3K27me3 levels (Fig. 2g) . This result is consistent with prior reports suggesting that activated AKT induces genome-wide changes in H3K27me3 (ref. 34 ) via phosphorylation and suppression of EZH2 35 . These experiments suggest RAS-PI3K activation attenuates the oncogenic effects of Ezh2 Y641F , explaining the inability of NRas Q61K to accelerate melanoma formation.
Ezh2 activity is required for tumor maintenance
Next we investigated whether Ezh2 inhibition could suppress tumor growth in these mice. shRNA-mediated knock-down of Ezh2 in cell lines derived from the mouse melanomas described above resulted in significant growth inhibition (P < 0.01, Fig. 3a,b) , suggesting that Ezh2 is required not only for tumor initiation but also maintenance. To determine the importance of Ezh2 enzymatic activity, we supplemented these genetic results with a pharmacological approach. We treated cell lines derived from TyrCRE ERT2 BRaf V600 Ezh2 Y641F/+ melanoma with three EZH2 inhibitors: UNC1999 (ref. 36 ), GSK126 (ref. 37 ) and a previously unpublished SAM-competitive pyridinone inhibitor, JQEZ5. The Constellation and Epizyme inhibitors were not available to us for comparative analysis at the times of these studies. JQEZ5 was designed as an open-source compound with high potency and bioavailability, is ~10-fold selective for EZH2 over EZH1, and exhibits in vitro activity against the Y646F mutant in a homogenous assay ( Supplementary Fig. 6a, b) . In a panel of Ezh2 +/+ or Ezh2 Y641F melanoma cell lines, UNC1999 and GSK126 showed EC50s of greater than 3.5μM regardless of Ezh2 genotype (ratio of average EC50 WT /EC50 Y641F = 1.4 for both agents, Supplementary Fig. 6c ). In contrast, JQEZ5 was nearly 5-fold more potent in Ezh2 Y641F melanoma cell lines than in wild-type cell lines (EC50 Y641F = 860nM vs.
EC50 WT = 4.0μM, Supplementary Fig. 6c, d ). Treatment with all three compounds resulted in decreased H3K27me3 levels, with JQEZ5 being effective at nanomolar concentrations ( Fig. 3c, d , Supplementary Fig. 7a , b). All three compounds induced cell cycle arrest within 3-5 days of treatment at their respective EC50s (Fig. 3e) . Sub-micromolar exposures of JQEZ5 of greater than 1 week also induced cell death in Ezh2 Y641F mutant lines ( Supplementary Fig. 7c, d ). To determine if Ezh1, an Ezh2 homolog, was responsible for residual H3K27me3 signal after Ezh2 inhibition (Fig. 3c, d ), we knocked down Ezh1 in mutant melanoma cell lines treated with JQEZ5. Ezh1 knockdown did not affect cell growth or global H3K27me3 levels in inhibitor-treated Ezh2 +/+ or Ezh2 Y641F cell lines ( Supplementary Fig. 8 ), suggesting that Ezh1 does not compensate for Ezh2 inhibition in these melanomas.
We next assessed the anti-tumor efficacy of EZH2 inhibitors in vivo. We studied lymphoma in CD19 CRE Ezh2 Y641F+ mice with autochthonous tumors, and melanoma in immunodeficient mice transplanted with cell lines derived from the tumors of TyrCRE ERT2 B-Raf V600E Pten L/+ Ezh2 Y641F/+ or TyrCRE ERT2 B-Raf V600E Pten L/L mice. Once tumors reached 10 mm 3 in size, mice were treated with vehicle, the B-Raf inhibitor Dabrafenib (25mpk daily), JQEZ5 (50mpk, daily), or a combination of both. JQEZ5 was selected for these studies as it was the most efficacious compound in vitro, exhibited low toxicity, with favorable pharmacokinetic properties in vivo, comparable to those of Ezh2 inhibitors currently in clinical trials ( Supplementary Fig. 6c-e) . As single agents, Dabrafenib and JQEZ5 resulted in tumor growth inhibition in both Ezh2 +/+ and Ezh2 Y641F/+ tumors, with Dabrafenib being the more potent agent. Combinatorial treatment with Dabrafenib and JQEZ5 resulted in additive activity in Ezh2 Y641F/+ but not Ezh2 +/+ tumors (Fig. 3f) . After developing lymphoma as assessed by the appearance of pathological symptoms, CD19 CRE/+ Ezh2 Y641F/+ animals were treated with vehicle or 50mpk of JQEZ5 by daily intraperitoneal injection. Six days of treatment with JQEZ5 complete cleared the malignant population (B220 low Mac1 low ) from the spleen, without depleting normal B-cells (Fig. 3g, h,  Supplementary Fig. 6f ). These data show that a selective inhibitor of EZH2 has potent single-agent activity in vivo in an autochthonous model of Ezh2 Y641F -mutant B-cell lymphoma, and is effective in combination with a B-RAF inhibitor in RAF-mutant melanoma.
Effects of Ezh2 Y641F on RNA expression
To understand the molecular effects of Ezh2 activation in B-cells and melanoma, we performed RNA-seq and H3K27me3 chromatin immunoprecipitation and sequencing (ChIPseq). As the expression of Ezh2 Y641F in young adult mice did not alter B-cell development ( Supplementary Fig. 2 ), for B-cell analysis, we examined CD19+ cells isolated from the spleen of 8-week-old CD19 CRE/+ Ezh2 Y641F/+ and CD19 CRE/+ Ezh2 +/+ littermates. For melanoma experiments, we screened >20 cell lines derived from tumors of TyrCRE ERT2 BRaf V600 Pten L/+ Ezh2 Y641F/+ mice, and sub-cloned two lines that had not recombined the Ezh2 allele. Through in vitro 4-OH-tamoxifen treatment, these lines yielded isogenic lines differing only in expression of the Ezh2 mutation. In B-cells, 213 transcripts were upregulated and 346 were repressed by Ezh2 Y641F (P < 0.01, Supplementary Table 1) , whereas 563 genes were upregulated and 746 were downregulated in the Ezh2 Y641F melanoma cells (P < 0.01, Supplementary Table 2) . Gene set enrichment analysis (GSEA) in both B-cells and melanoma cell lines expressing Ezh2 Y641F revealed a significant concordance between genes downregulated in cells expressing EZH2 Y641F and genes silenced by the PRC2 complex 38, 39 (Fig. 4a, Supplementary Table 3 ). In separate biological replicates, we confirmed by qRT-PCR the altered expression of 8 transcripts identified by RNA-seq ( Supplementary Fig. 9 ).
The RNA-seq analysis yielded two surprising results. First, in B-cells, GSEA indicated that transcripts repressed by expression of Ezh2 Y641F were enriched for genes known to be repressed by C-MYC activation in other B-lineage cells [40] [41] [42] (Fig. 4b; Supplementary Fig.  10a, b; Supplementary Table 3) . Enrichment for C-MYC targets was also observed in Ezh2 Y641F expressing melanoma cell lines, albeit with less significance than in lymphoma (Supplementary Table 3 ). To directly assess the relationship between C-MYC and EZH2 in B-cells, we first used a B-cell lymphoma line (P493-6) 43 with tet-inducible C-MYC expression. Upon activation of C-MYC, EZH2 expression increased in a time-dependent manner (Fig. 4c) , resulting in increased global H3K27me3 (Fig. 4d) . We next analyzed C-MYC ChIP datasets available through the ENCODE consortium, looking for enrichment of C-MYC and MAX (a dimerization partner of C-MYC) at the EZH2 locus. Our analysis showed multiple C-MYC/MAX binding sites at the EZH2 transcription start site (TSS), in the EZH2 promoter, and at an enhancer ~50 kb 5′ to the TSS in multiple cell types, including lymphoma (Supplementary Fig 10c) . The C-MYC/MAX binding peaks were associated with strong peaks of H3K27 acetylation (H3K27Ac, Supplementary Fig. 10c ), suggesting transcriptional activation. These findings agree with prior studies of C-MYC and EZH2 expression 44, 45 , and suggest that some of the oncogenic effects of C-MYC amplification in B-cell lymphoma may be mediated by EZH2 activation.
A second surprising finding of the RNA-seq analysis of Ezh2 Y641F cells was an increase in the expression of many genes known to be directly repressed by the PRC2 complex and EZH2, such as Hoxc4, Hoxc9 and Meis1 in B-cells ( Supplementary Fig. 9 , Supplementary  Table 1 ) and the Hoxd gene cluster in melanoma cell lines (Supplementary Table 2 ). Mining Epigenomics Roadmap 46 data, we noted that many of the PRC2-regulated genes activated by Ezh2 Y641F were densely covered with repressive H3K27me3 in normal B-cells, suggesting they are silenced in healthy cells (Supplementary Fig. 11a ). In contrast, many of the genes most strongly repressed by Ezh2 Y641F lacked H3K27me3 in normal B-cells, and instead were located near enhancer elements marked with H3K27Ac ( Supplementary Fig. 11b ). This suggests that Ezh2 Y641F activates certain silenced genes and silences certain activated genes.
Ezh2 Y641F expression causes global re-distribution of H3K27me3
To determine if this apparent pattern was a direct effect of altered H3K27me3 abundance, we performed H3K27me3 ChIP-seq. Principal component analysis (PCA, Fig. 5a ) of the differentially expressed ChIP-seq peaks showed that the first PC of the dataset reflected Ezh2 genotype, whereas a second, weaker PC reflected tissue of origin (B-cells vs. melanoma). Treatment with JQEZ5 altered the peak pattern in Ezh2-mutant melanoma cell lines along the first PC towards untreated isogenic WT cells (Fig. 5a ), suggesting EZH2 inhibition significantly 'normalized' the peak pattern in Ezh2 Y641F expressing cells. This impression was confirmed when H3K27me3 was visualized across the entire genome ( Supplementary Fig. 12a ).
We next performed hierarchical clustering of these samples by genome-wide, nonoverlapping 5 kb windows that exhibited dynamic H3K27me3 between Ezh2 +/+ and matched Ezh2 Y641F/+ cells based on a standard deviation threshold ( Supplementary Fig. 12b,  c) . This analysis revealed two major clusters: one with increased H3K27me3 in Ezh2 +/+ samples, and a larger cluster with increased H3K27me3 in Ezh2 Y641F/+ samples. These clusters appeared in both B-cells and melanoma cells with significant overlap of dynamic regions ( Supplementary Fig. 12b, c) . The finding of a large number of loci with dense H3K27me3 in Ezh2 +/+ samples that is lost in Ezh2 Y641F/+ B-cells or melanoma was unexpected given the presumed hypermorphic activity of the mutant enzyme, yet such loci were even more obvious using a 'peak calling' algorithm (MACS 47 ), which assigns statistical significance to each dynamic peak. A 'volcano plot' of the log-transformed foldchange of H3K27me3 peak signal versus log transformed P value demonstrated that the peaks with most highly significant change between Ezh2 +/+ and Ezh2 Y641F/+ samples were those that decreased 2-4 fold in Ezh2 Y641F/+ cells. As in the PCA, there was a significant restoration of the wild-type peak pattern in Ezh2 Y641F/+ melanoma cells by JQEZ5 treatment (Fig. 5b, Supplementary Fig. 12a ). We considered the possibility that this apparent decrease in peaks in Ezh2 Y641F/+ cells reflected an artifact of normalization, as a relative increase in genome-wide H3K27me3 could dilute the intensity of the highest peaks seen in Ezh2 +/+ cells. However, we discounted this possibility for two reasons. First, the fold-decrease of H3K27me3 at certain loci (Fig. 5b) greatly exceeded the global increase in H3K27me3 by western analysis (Fig. 1b, j) , suggesting dilution alone as an unlikely cause. Moreover, the observed changes in peak height correlated with RNA expression at specific loci: for example, the significant increase in HoxC expression in Ezh2 Y641F/+ B-cells correlated with H3K27me3 loss at this locus (Fig. 5c) , whereas Igf1 repression in Ezh2 Y641F/+ melanoma cells lines occurred in the setting of greatly increased H3K27me3 at this locus (Fig. 5c ). These observations suggest that the expression of mutant Ezh2 causes a global redistribution of H3K27me3, from highly focal peaks apparent in Ezh2 +/+ samples to a larger number of broader, less focal peaks in Ezh2 Y641F/+ samples, with attendant changes in gene expression.
We analyzed the effects of Ezh2 Y641F expression on the distribution of H3K27me3 at promoter regions, TSS and gene bodies. Toward that end, we rank-ordered transcripts by level of expression in Ezh2 +/+ samples, and averaged the normalized H3K27me3 intensity ± 5 kb around the TSS for the top and bottom quartiles of expression (Fig. 5d) . Consistent with prior work 48 , this analysis showed increased H3K27me3 flanking the TSS of genes with the lowest expression (black), with an obvious 'spike' of H3K27me3 immediately 3′ to the TSS. Expression of Ezh2 Y641F led to a relative decrease in H3K27me3 in the least transcribed genes with little effect on H3K27me3 at transcripts in the highest quartile of expression. This observation suggests that the increased expression of some transcripts in Ezh2 Y641F mutant cells (Supplementary Table 1 , 2) results from a paradoxical loss of H3K27me3 around the TSS's of certain PRC2-repressed genes.
We next analyzed mean normalized H3K27me3 signal around the TSS (± 5 kb) of genes with a significant change in expression between Ezh2 +/+ and Ezh2 Y641F/+ cells (Supplementary Table 1 and 2). Genes upregulated in the presence of Ezh2 Y641F in both Bcells and melanoma cell lines exhibited decreased H3K27me3 signal around the TSS, particularly immediately 3′ to the TSS (Fig. 5e-left) . In contrast, genes that were downregulated in the presence of Ezh2 Y641F exhibited increased H3K27me3, starting on average more than 2 kb downstream of TSS (Fig. 5e-right) . These results are consistent with a prior report suggesting H3K27me3 in the gene body is strongly repressive, whereas promoter H3K27me3 can also be seen in actively transcribed genes 48 . To further consider this possibility, we analyzed H3K27me3 along the gene body [from TSS to Transcription Termination Site (TTS)] of transcripts differentially expressed between Ezh2 +/+ and Ezh2 Y641F/+ samples (Fig. 5f) . In contrast to the effects of Ezh2 mutations around the TSS, we observed a modest effect of Ezh2 Y641F on upregulated genes (P = 0.07), but a marked increase (P = 1.7e-15) of H3K27me3 in the gene body of downregulated genes (Fig. 5f ).
Finally, we analyzed the effect of the Ezh2 Y641F mutation on the entire genome, focusing on melanoma cell lines. Toward this end, we identified broad H3K27me3 domains in Ezh2 +/+ cells across the genome, and then compared the mean, normalized H3K27me3 signal 10 kb upstream and downstream of these domains in Ezh2 +/+ vs. Ezh2 Y641F/+ samples. Consistent with our peak-calling analysis (Fig. 5b) , we observed a dramatic decrease in H3K27me3 in Ezh2 Y641F/+ samples, which was largely restored with JQEZ5 treatment. Importantly, however, we observed an increase in H3K27me3 extending for more than 10 kb both 5′ and 3′ to these domains in Ezh2 Y641F/+ samples (Fig. 5g) . In aggregate, these results demonstrate that the Ezh2 Y641F mutant enzyme causes a global redistribution of H3K27me3 away from focal peaks (e.g. near the TSS) across broad regions including gene bodies and intergenic regions.
DISCUSSION
Consistent with prior work 21 , we show that under physiological conditions, global H3K27me3 levels are elevated in cells expressing Ezh2 Y641F , consistent with a model of increased enzymatic activity. On the other hand, through H3K27me3 ChIP-seq analysis, we provide evidence that the Y641F mutation does not monotonically increase H3K27me3, but rather redistributes the H3K27me3 mark across the genome with complex effects on transcription. Through integrated analysis of ChIP-seq and RNA-seq, we observe loci where Ezh2 Y641F samples show reduced H3K27me3 and increased expression, and vice versa. In particular, we note that the effects are not uniform with regard to genomic regions: the mutation seems to favor H3K27me3 over large regions-at gene bodies and intergenic regions-at the expense of focal peaks near the TSS. While the mechanistic basis for this preference in unclear, the recent solution of the crystal structure of the yeast (C. Thermophilus) PRC2 complex provides tantalizing clues 49 . In this work, the authors suggest that wild-type EZH2 is allosterically activated when EED binds H3K27me3, through reorganization of the complex that alters the lysine substrate channel of the enzyme in a manner similar to the A682 SET domain mutation 50 . This structure suggests that the yeast amino acid (Y826) homologous to Y646 also participates in the formation of this substrate channel, providing the possibility that this mutation reduces the need for H3K27me3-EED stimulation of the enzymatic complex, thereby creating a more promiscuous complex. Such a complex would be expected to increase H3K27me3 at most nucleosomes. If some cofactor (e.g. SAM) for tri-methylation were limiting, however, such a complex might also show reduced H3K27me3 at focal peaks that perhaps more strongly require the stimulatory effects of the H3K27me3-EED interaction in cells expressing the wild-type complex.
Regardless of the precise mechanistic details, however, the observations that Ezh2 Y641F expression decreases H3K27me3 at many loci ( Fig. 5b-g; Supplementary Fig. 12 ) and that this effect is largely reversed with an EZH2 inhibitor ( Fig. 5b, g; Supplementary Fig. 12a) are not consistent with the notion that this is a strictly hypermorphic allele. Rather, we believe the allele should more properly be considered neomorphic, perhaps as a result of reduced requirements for H3K27me3-mediated auto-activation.
Therapeutically, these results have direct implications for human cancers harboring SET domain mutations of Ezh2. First, the overlap of gene-expression signatures of Ezh2 activation and c-Myc repression in B-lineage cancers (Fig. 4b) and lack of cooperation between c-Myc over-expression and Ezh2 mutation in lymphomagenesis (Fig. 1e) suggests the intriguing possibility that EZH2 mediates some of the transforming effects of C-MYC in lymphoma. Just as recent reports suggesting BAP1 51 , ARID1a 52 and SNF5 53 mutations predict sensitivity to EZH2 inhibitors, this finding suggests a rationale for testing EZH2 inhibitors in B-cell neoplasms characterized by strong C-MYC activation. Additionally, we report a newly developed, potent pharmacologic EZH2 inhibitor, JQEZ5, with excellent in vitro and in vivo properties and which demonstrates marked in vivo anti-tumor activity in a faithful model of Ezh2 mutant cancer (Fig. 3, Supplementary Fig. 6 ). Lastly, the discovery of the exquisite and specific cooperation between activating genetic events of EZH2 and B-RAF, but not N-RAS (Fig. 2, Supplementary Fig. 5 ), predicts synergistic activity of combined therapy with RAF inhibitors (e.g. dabrafenib or vemurafenib) and EZH2 inhibitors in this heretofore unappreciated melanoma sub-type representing 3-9% of all melanoma patients.
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